Arena Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27
SAN DIEGO, Feb. 21, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 9:30 AM EST. The conference will take place February 27 – March 1, 2019 at the Lotte New York Palace in New York City.
A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event.
About Arena
Pharmaceuticals
Arena Pharmaceuticals is driven to
deliver novel, transformational medicines with optimized
pharmacology and pharmacokinetics to patients globally. Arena's
proprietary pipeline includes multiple potentially first- or
best-in-class assets with broad clinical utility. Etrasimod (APD334), with potential
utility in a broad range of immune and inflammatory conditions, is
being evaluated in later-stage clinical programs in ulcerative
colitis (UC) and Crohn's disease, as well as in programs for other
indications such as atopic dermatitis. Arena is also evaluating
olorinab (APD371) in a Phase 2 program
for gastrointestinal pain. Arena continues to assess other earlier
research and development stage drug candidates, including
APD418 for decompensated heart failure.
Arena's licensee, United Therapeutics, is evaluating ralinepag in a
Phase 3 program for pulmonary arterial hypertension (PAH).
Arena has additional license agreements and partnerships, including with Everest Medicines Limited (etrasimod in Greater China and select Asian countries), Boehringer Ingelheim International GmbH (undisclosed target – preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® – marketed product).
Forward-Looking Statements
Certain
statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. These
forward-looking statements may be accompanied by words such as
"will," "driven to," "potentially," "potential," "evaluating for,"
"being evaluated," "assess for," or words of similar meaning, or
they may be identified by the fact that they do not relate strictly
to historical or current facts. Such forward-looking statements
include, without limitation, statements about Arena's upcoming
presentation and audio webcast and Arena's drive, focus, goals,
strategy, clinical and research and development programs,
collaborations, and licenses. For such statements, Arena claims the
protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from Arena's
expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include the timing
and outcome of research, development and regulatory review is
uncertain; clinical programs may not proceed at the time or in the
manner expected or at all; results of clinical trials and other
studies are subject to different interpretations and may not be
predictive of future results; and other risks related to developing
and commercializing drugs; as well as those factors disclosed in
Arena's filings with the Securities and Exchange Commission (SEC),
including but not limited to Arena's Quarterly Report on Form 10-Q
for the quarter ended September 30, 2018, which was
filed with the SEC on November 8, 2018. These
forward-looking statements represent Arena's judgment as of the
time of this release. Arena disclaims any intent or obligation to
update these forward-looking statements, other than as may be
required under applicable law.
Corporate Contact:
Kevin
R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
[email protected]
858.210.3636
Media Contact:
Matt Middleman,
MD
LifeSci Public Relations
[email protected]
646.627.8384
View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-8th-annual-svb-leerink-global-healthcare-conference-on-february-27-300799306.html